Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.53 |
| ▸ | WNK1 | Q9H4A3 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8884398 | 1.00 | ALDH1A1 (0.58) | ALDH1A1KDM4EMAPTMAPK1KMT2A | |
| SCHEMBL8885726 | 0.98 | ALDH1A1 (0.59) | ALDH1A1KDM4EMAPTMAPK1KMT2A | |
| SCHEMBL17582804 | 0.95 | MAPT (0.57) | ALDH1A1KDM4EMAPTMAPK1KMT2A | |
| SCHEMBL7177890 | 0.92 | MAPT (0.59) | ALDH1A1KDM4EMAPTMAPK1KMT2A | |
| SCHEMBL7541568 | 0.88 | HCAR3 (0.64) | ALDH1A1MAPTMAPK1KMT2AMEN1 | |
| SCHEMBL8883112 | 0.87 | MAPT (0.51) | ALDH1A1KDM4EMAPTMAPK1KMT2A | |
| SCHEMBL14092691 | 0.85 | HCAR3 (0.57) | ALDH1A1KDM4EMAPTMAPK1KMT2A | |
| Bromide SCHEMBL11097137 | 0.85 | MAPT (0.58) | ALDH1A1KDM4EMAPTMAPK1KMT2A | |
| SCHEMBL8885781 | 0.84 | ALDH1A1 (0.52) | ALDH1A1KDM4EMAPTMAPK1KMT2A | |
| SCHEMBL8884305 | 0.84 | ALDH1A1 (0.49) | ALDH1A1KDM4EMAPTMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101166529-B | Benzotriazole derivatives as cannabinoid receptor antagonists | JANSSEN PHARMACEUTICA NV | 2011-11-16 | — | — | CN | disclosed |
| EP-1874304-B1 | BENZOTRIAZOLE DERIVATIVES AS CANNABINOID RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2009-07-15 | — | — | EP | disclosed |
| US-20080194656-A1 | Benzotriazole Derivatives as Cannabinoid Receptor Antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-14 | — | — | US | disclosed |
| CN-101166529-A | Benzotriazole derivatives as cannabinoid receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2008-04-23 | — | — | CN | disclosed |
| EP-1874304-A2 | BENZOTRIAZOLE DERIVATIVES AS CANNABINOID RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006117307-A2 | BENZOTRIAZOLE DERIVATIVES AS CANNABINOID RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-09 | — | — | WO | disclosed |
| US-5661169-A | HAVE AFFINITY FOR VASOPRESSIN AND/OR OXYTOCIN RECEPTORS | SANOFI (FR) | 1997-08-26 | — | — | US | disclosed |
| US-5585394-A | INHIBITOR, ANTAGONIST OF VASOPRESSIN OR OXYTOCIN | SANOFI (FR) | 1996-12-17 | — | — | US | disclosed |
| EP-0694536-A1 | 1-Benzyl-1,3-dihydro-2H-benzimidazol-2-one derivatives, their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1996-01-31 | — | — | EP | disclosed |
| EP-0636614-A1 | Derivatives of 1-benzenesulfonyl-1,3-dihydro-2H-benzimidazol-2-one, their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1995-02-01 | — | — | EP | disclosed |
| EP-0315959-B1 | Quinoxaline compounds and their preparation and use | NOVO NORDISK AS (DK) | 1994-03-02 | — | — | EP | disclosed |
| US-5026704-A | Neuroleptic agent, quisqualate-antagonist | NOVO NORDISK A/S (DK) | 1991-06-25 | — | — | US | disclosed |
| US-4948794-A | NEUROLEPTIC AGENTS | A/S FERROSAN (DK) | 1990-08-14 | — | — | US | disclosed |
| EP-0315959-A2 | Quinoxaline compounds and their preparation and use | NOVO NORDISK A/S (DK) | 1989-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194656-A1 | Benzotriazole Derivatives as Cannabinoid Receptor Antagonists | CNR1, CNR2, HTR3C | ALDH1A1 858/4885KDM4E 3439/4885MAPT 2683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.